aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma Advances Efzofitimod to Phase 3 for Pulmonary Sarcoidosis

aTyr Pharma announced its Q1 2026 results and a corporate update, highlighting a clear path forward for efzofitimod in pulmonary sarcoidosis. Following a Type C meeting with the FDA, the company plans to submit an Investigational New Drug (IND) application in June 2026 for a new global Phase 3 study. This study will evaluate efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, using Forced Vital Capacity (FVC) as the primary endpoint and KSQ-Lung score as a key secondary endpoint. Additionally, enrollment for the Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD is on track for completion in the first half of 2026. The company ended Q1 2026 with $68.3 million in cash and investments.

• aTyr Pharma is advancing efzofitimod into a new global Phase 3 study for chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. This follows a positive Type C meeting with the FDA, with an IND submission planned for June 2026. The 54-week, randomized, double-blind, placebo-controlled study will enroll up to 372 patients, evaluating 5.0 mg/kg efzofitimod dosed intravenously every three weeks.
• The planned Phase 3 study for efzofitimod in pulmonary sarcoidosis will utilize Forced Vital Capacity (FVC) as its primary endpoint, measuring change from baseline at week 48. The King’s Sarcoidosis Questionnaire (KSQ)-Lung score will serve as the key secondary endpoint, also assessing change from baseline at week 48, providing a comprehensive evaluation of efficacy and patient-reported outcomes.
• The Phase 2 EFZO-CONNECT™ study, investigating efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD), is on track to complete enrollment in the first half of 2026. Furthermore, aTyr Pharma's investigational new drug candidate, ATYR0101, which targets myofibroblast apoptosis and fibrosis reduction, had a poster accepted for presentation at the Extracellular Matrix Pharmacology Congress in June 2026.
• aTyr Pharma reported a solid financial position, ending the first quarter of 2026 with $68.3 million in cash, cash equivalents, restricted cash, and investments. Research and development expenses for the quarter were $7.3 million, primarily supporting the EFZO-FIT™ and EFZO-CONNECT™ studies, while general and administrative expenses totaled $4.1 million.

Efzofitimod's Planned Phase 3 Design for Pulmonary Sarcoidosis

The RESOLVE Lung trial represents the most significant recent Phase 2 study for pulmonary sarcoidosis, testing namilumab (anti-GM-CSF monoclonal antibody) in a double-blind, placebo-controlled design. This multinational trial builds on insights from earlier landmark studies including the pivotal infliximab trials and emerging consensus on optimal endpoint selection for sarcoidosis clinical development.

Addressing Unmet Needs in Pulmonary Sarcoidosis Treatment

Current treatment approaches for pulmonary sarcoidosis face significant challenges that impact patient outcomes and clinical decision-making. The lack of standardized treatment protocols, combined with the unpredictable disease course and highly variable manifestations, creates substantial therapeutic management difficulties. These limitations are compounded by insufficient evidence from controlled trials and the absence of consensus on disease activity monitoring.

• Lack of treatment standardization and consensus — Treatment protocols for pulmonary sarcoidosis have not been standardized, with no established consensus on monitoring disease activity, despite the unpredictable course and highly variable manifestations that may not respond effectively to treatment in all patients

• Limited evidence base for therapeutic decisions — Available information remains limited despite increased research in recent years, with particularly insufficient data from controlled trials to guide treatment of patients with extrapulmonary sarcoidosis manifestations

• Suboptimal outcomes with current therapies — Therapeutic benefits do not affect long-term outcomes, effective treatments are unavailable for advanced fibrocystic pulmonary disease, and clinical resolution rates have declined to 17.9% at 2 years and 29.9% at 5 years, lower than historically reported

• Glucocorticoid-related treatment challenges — Optimal doses of oral glucocorticoids remain unknown, prolonged use may be required for symptom control and disease stabilization, and growing evidence of glucocorticoid-related toxicities is prompting a paradigm shift toward reduced steroid use

• Limited efficacy of alternative therapeutic options — Bioagent therapies have not demonstrated superior efficacy and safety over corticosteroids, infliximab shows only modest lung function improvements in steroid-resistant patients, and treatment studies for sarcoidosis-associated progressive pulmonary fibrosis have been underpowered to demonstrate clear benefits

• Access and regulatory barriers to emerging therapies — The use of promising monoclonal anti-TNF agents remains limited by lack of licensing and high costs, while uncertainty persists regarding optimal treatment approaches for sarcoidosis-associated pulmonary hypertension with phosphodiesterase-5 inhibitors, prostaglandin analogs, or endothelin antagonists

Efzofitimod's Pivotal Step in Pulmonary Sarcoidosis

The recent corporate update from aTyr Pharma marks a pivotal moment for efzofitimod, signaling a clear and accelerated path toward potentially transforming the treatment landscape for pulmonary sarcoidosis. With plans to submit an Investigational New Drug (IND) application for a new global Phase 3 study in June 2026, the company is committing to a rigorous evaluation of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, using Forced Vital Capacity (FVC) as the primary endpoint. This focus on FVC is critical, as it directly measures lung function, a key indicator of disease progression and patient well-being.

Efzofitimod stands out due to its novel mechanism of action as a first-in-class biologic that selectively modulates neuropilin-2 (NRP2), a receptor highly expressed in sarcoidosis granulomas. This targeted approach aims to downregulate immune responses and inflammation, offering a potential alternative to current corticosteroid-centric therapies, which are often associated with significant toxicities and impaired quality of life. Early clinical data from a Phase 1b/2a study have been encouraging, showing efzofitimod to be well tolerated, with dose-dependent improvements in patient-reported outcomes and a trend toward improved lung function. A subsequent post-hoc analysis further strengthened this, indicating a lower relapse rate and increased FVC in patients receiving therapeutic doses, suggesting a valuable steroid-sparing effect.

However, the journey ahead is not without its challenges. While the post-hoc analysis showed promising FVC data, the initial Phase 1b/2a study reported only a non-significant trend in lung function improvement, and a broader meta-analysis characterized FVC improvements as modest. The upcoming Phase 3 trial will need to demonstrate robust and statistically significant FVC improvements to meet its primary endpoint and differentiate itself in an evolving therapeutic space. The sarcoidosis market is seeing increased interest, with established anti-TNF agents and emerging therapies like JAK and mTOR inhibitors. Efzofitimod will need to carve out a distinct clinical profile, perhaps through superior efficacy, a favorable safety profile, or a clear steroid-sparing advantage, to gain significant traction. Furthermore, the limitations of prior studies, including small sample sizes and heterogeneity, underscore the importance of the large-scale Phase 3 to provide definitive evidence. Beyond pulmonary sarcoidosis, the ongoing Phase 2 EFZO-CONNECT™ study in systemic sclerosis-associated interstitial lung disease (SSc-ILD) highlights the broader potential of efzofitimod's mechanism across other fibrotic lung conditions, offering a strategic diversification of its clinical utility. If successful, efzofitimod could represent a significant step forward for patients grappling with these debilitating diseases.